NGM - NGM Biopharmaceuticals Inc Stock Price, Fair Value and News

$1.54

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NGM Price Action

NGM RSI Chart

NGM Valuation

NGM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NGM Fundamentals

NGM Revenue

NGM Earnings

NGM Profitability

NGM Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	36.6M	29.7M	22.4M	4.4M
2022	77.3M	68.8M	58.1M	55.3M
2021	84.6M	81.6M	76.7M	77.9M
2020	102.4M	96.8M	98.7M	87.4M
2019	115.6M	118.8M	119.6M	103.5M
2018	85.0M	92.9M	100.8M	108.7M
2017	0	0	0	77.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 which is in phase I clinical trial for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

CEO	Dr. David J. Woodhouse Ph.D.
WEBSITE	ngmbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	239